Glenmede Trust’s Amylyx Pharmaceuticals AMLX Stock Holding History

Glenmede Trust’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$246K	Buy	+13,685	New	+$212K	﹤0.01%	1257

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Glenmede Trust's AMLX Position: Q2 2026 in Review

Glenmede Trust opened a new position in Amylyx Pharmaceuticals (AMLX) in Q2 2026: 13,685 shares worth $246K. The stake represents ﹤0.01% of the portfolio and ranks #1257 among its holdings.

206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Glenmede Trust held 13,685 shares of Amylyx Pharmaceuticals worth $246K as of Q2 2026.
Amylyx Pharmaceuticals was a new Glenmede Trust position in Q2 2026.
Amylyx Pharmaceuticals made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1257 holding.
206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.